N@N

(OTCBB: RGIN) Has PermaDerm Designated as a Combination Product by the FDA

^{Published on 2011-04-11 04:35:17 - Market Wire}
 

NEW YORK, NY--(Marketwire - April 11, 2011) - Regenicin, Inc. (OTCBB: [ RGIN ]) filed an 8-K on April 7^th stating that they have received "combination product designation" by the FDA.

As fewer "blockbuster" drugs make it to market, drugs and devices are increasingly joining together creating a new sector estimated to top $11 billion. Combination products emerging growth has been outlined in an article published by the Medical Device and Diagnostic Industry ([ http://www.mddionline.com/article/marketing-combination-products ]).

Recent successful combination devices that have made it to market are, Noven Pharmaceuticals transdermal patch for treatment of attention deficit disorder (ADD) and Boston Scientifics Corp (NYSE: [ BSX ]) drug-eluting stent, Taxus.

For more information on Regenicin, Inc. please visit [ www.proactivenewsroom.com ]

Other active stocks are Tengion, Inc (NASDAQ: [ TNGN ]) and Genzyme Corp (NASDAQ: [ GENZ ])

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.